Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01953341 | Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines | PHASE1 | COMPLETED | 74 | — | — | Oct 1, 2013 | Nov 1, 2014 | Dec 9, 2014 | 1 | United States |
Treatment-emergent adverse events, including changes in vital signs, 12-lead ECGs, clinical laboratory safety tests, and physical and neurological assessments
| Arm | Type | Description |
|---|---|---|
| AMG 333 | EXPERIMENTAL | Subjects will receive a single oral dose of AMG 333 . |
| Placebo | PLACEBO_COMPARATOR | Subjects will receive a single oral dose of placebo. |
| Name | Type | Description |
|---|---|---|
| AMG 333 | DRUG | Oral administration available in varying dose strength. |
| Placebo | DRUG | Placebo containing no active drug |
Inclusion Criteria: * Healthy male and female subjects with or without migraines ≥18 and ≤55 years of age at the time of screening, with no history or evidence of clinically relevant medical disorders as determined by the investigator in consultation with the Amgen physician. Exclusion Criteria: ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 15 | PHASE3 | Atogepant, Topiramate, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant, Rimegepant/BHV3000, Zavegepant, Various, Rimegepant for acute migraine treatment |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1, erenumab-aooe |
| Ki Health Partners. LLC | RVNC | 1 | — | Daxibotulinumtonix A |